Clinical Trial

Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2026 (before its estimated June 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the imaging characteristics of \[⁶⁸Ga\]Ga-GS24-B2-250-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-250-T), \[⁶⁸Ga\]Ga-GS24-B2-268-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-268-T), \[⁶⁸Ga\]Ga-GS24-B2-237-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-237-T), and \[⁶⁸Ga\]Ga-PSMA-11 Injection (abbreviated as ⁶⁸Ga-PSMA-11) as PET/CT imaging agents in patients with prostate cancer.
Trial Details
NCT Number NCT07365397
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Prostate Cancer
Enrollment 9 participants
Start Date 2026-01-19
Primary Completion 2026-06-14 (estimated)
Study Completion 2026-07-26 (estimated)
Updated on ClinicalTrials.gov 2026-01-26